ICON plc. to Host Annual General Meeting of Shareholders on July 25, 2023
July 11, 2023
🌥️Trending News
ICON ($NASDAQ:ICLR) plc., a leading global provider of medical information and technology services, is set to host its Annual General Meeting of Shareholders on July 25, 2023. The meeting will take place virtually, giving shareholders the opportunity to learn more about ICON’s business and operations in an accessible way. Through their medical information and technology services, they are pioneering the transformation of healthcare and clinical research. They provide clinical trial services, regulatory services, data analytics solutions, drug safety monitoring, and more.
In addition to their services for biopharmaceutical companies, ICON also provides technology solutions to hospitals and healthcare systems. The meeting will provide investors with the opportunity to engage in discussions with the Board of Directors and senior management team.
Price History
At the start of the day, ICON PUBLIC stock opened at $240.4, however at the day’s close, the price had dropped by 0.9%, closing at $240.8. This was lower than the previous closing price of $243.0. The AGM is expected to be an important event for shareholders, as the company will update them on its performance during the previous year and provide guidance for the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Icon Public. More…
| Total Revenues | Net Income | Net Margin |
| 7.82k | 509.99 | 7.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Icon Public. More…
| Operations | Investing | Financing |
| 511.9 | -154.37 | -628.73 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Icon Public. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 17.29k | 8.63k | 103.98 |
Key Ratios Snapshot
Some of the financial key ratios for Icon Public are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 40.1% | 28.0% | 10.5% |
| FCF Margin | ROE | ROA |
| 4.6% | 6.0% | 3.0% |
Analysis
At GoodWhale, we recently conducted an analysis of ICON PUBLIC‘s fundamentals. Based on our Star Chart, ICON PUBLIC has a high health score of 8/10, meaning that it is capable of safely riding out any crisis without the risk of bankruptcy. In terms of growth, ICON PUBLIC is strong in this category. However, the company’s profitability is only medium-strong and its assets and dividends are weak. This led us to categorize ICON PUBLIC as a ‘cheetah’ type of company, which achieves high revenue or earnings growth but is considered less stable due to lower profitability. Investors who are looking for high-growth opportunities and are comfortable with the associated risks may be interested in ICON PUBLIC. The company’s strong revenue growth and low debt present an interesting opportunity for those willing to take a risk. More…
Peers
Icon PLC, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, offers a comprehensive portfolio of services. The company has over 30 years of experience in clinical research and has conducted over 10,000 clinical trials in over 100 countries. Icon has a team of over 8,000 employees, including 1,200 clinical research professionals. The company’s main competitors are Bioqual Inc, Imagion Biosystems Ltd, and Aclaris Therapeutics Inc.
– Bioqual Inc ($OTCPK:BIOQ)
The company’s market cap is 5.24M as of 2022 and its ROE is 265.57%. The company is engaged in the development of therapeutics to treat patients with serious and life-threatening diseases.
– Imagion Biosystems Ltd ($ASX:IBX)
Imagion Biosystems Ltd is a medical technology company that develops and commercializes molecular imaging products for the early detection of cancer. The company has a market capitalization of $31.4 million and a return on equity of -59.36%. Imagion Biosystems’ products are based on magnetic nanoparticles that are injected into the body and selectively bind to cancer cells. The nanoparticles are then detected using a magnetic resonance imaging (MRI) scanner, which allows for the early detection of cancer.
– Aclaris Therapeutics Inc ($NASDAQ:ACRS)
Aclaris Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of drugs for the treatment of dermatological and immunological disorders. The company has a market cap of 1.01B as of 2022 and a return on equity of -25.42%. Aclaris Therapeutics Inc is headquartered in Malvern, Pennsylvania.
Summary
ICON plc’s Annual General Meeting of Shareholders (AGM) will take place on July 25, 2023. Investors looking to gain insight into the company’s financial performance and future outlook should carefully consider the information provided at the AGM. Analysts should pay attention to ICON’s financial results and progress over the past year, as well as their short-term and long-term strategy for growth. Investors should also assess ICON’s competitive positioning within the industry, their cash flow and balance sheet, capital expenditure plans, and other key metrics that will affect their investment decisions.
The AGM is also an opportunity to hear from company executives and ask questions about the future of the business. Ultimately, investors should use the AGM as an opportunity to gain valuable insight into the strength of ICON plc as an investment opportunity.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
